AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29105489 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-term CHS + vitamin C
Number of subjects: 90
Study 29105489 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term CHS (20 days)
Number of subjects: 90
Study 29105489 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term CHS + vitamin C
Number of subjects: 90
Study 29105489 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 26449267 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) for 3 weeks
Number of subjects: 0
Study 25784660 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma phospholipid t-16:1n9
Number of subjects: 4210
Study 25784660 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma phospholipid t-18:1
Number of subjects: 4210
Study 25784660 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary trans fatty acids (TFAs)
Number of subjects: 4210
Study 25784660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary t-18:1
Number of subjects: 4210
Study 25784660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary t-18:2
Number of subjects: 4210
Study 25784660 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated dietary TFA after adjustment for other dietary habits
Number of subjects: 4210
Study 23299256 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular perturbations (3 and 6 degrees) in the coronal plane
Number of subjects: 11
Study 23299256 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular perturbations in the sagittal plane
Number of subjects: 11
Study 23299256 — intervention group
Group type: EXPERIMENTAL
Intervention: Translational perturbations (5 and 10 mm) in the sagittal plane
Number of subjects: 11
Study 23299256 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal angle malalignments
Number of subjects: 11
Study 23299256 — intervention group
Group type: EXPERIMENTAL
Intervention: Other alignment conditions
Number of subjects: 11
Study 20150450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified dosing of enteric‐coated mycophenolate sodium (EC‐MPS) - 2880 mg/d for days 0-14, 2160 mg/d for days 15-42, followed by 1440 mg/d
Number of subjects: 75
Study 20150450 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of enteric‐coated mycophenolate sodium (EC‐MPS) - 1440 mg/d
Number of subjects: 75
Study 20150450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified dosing of enteric‐coated mycophenolate sodium (EC‐MPS)
Number of subjects: 75
Study 20150450 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of enteric‐coated mycophenolate sodium (EC‐MPS)
Number of subjects: 75
Study 18321838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led storytelling intervention
Number of subjects: 11
Study 18321838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 15809365 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Number of subjects: 23
Study 15809365 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (Control)
Number of subjects: 23
Study 12464832 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted intervention to enhance communication; Women in the intervention group used information and decision preference profiles generated by the computer program at their clinic appointments.
Number of subjects: 749
Study 12464832 — intervention group
Group type: COMPARATOR
Intervention: Control group completed measures of decision preference before their clinic appointments.
Number of subjects: 749
Study 10707452 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised Controlled Trials (RCTs)
Number of subjects: 5
Study 10707452 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Clinical Trials (CCTs)
Number of subjects: 5
Study 10707452 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 5
Study 7571796 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic muscle training with high motion velocities (150 degrees/s, motion limit 0‐20‐90 degrees)
Number of subjects: 17
Study 7571796 — intervention group
Group type: COMPARATOR
Intervention: Common physiotherapy only
Number of subjects: 17
Study 7571796 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic muscle training with high motion velocities
Number of subjects: 17
Study 1683250 — intervention group
Group type: EXPERIMENTAL
Intervention: Abanoquil (0.5 micrograms kg‐1, intravenous bolus)
Number of subjects: 0
Study 7228474 — intervention group
Group type: EXPERIMENTAL
Intervention: Elsinore pills (ephedrine and caffeine)
Number of subjects: 132
Study 7228474 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylpropion
Number of subjects: 132
Study 7228474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 31533377 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional exercise and partly weight‐bearing walking starting two days after operation
Number of subjects: 64
Study 31533377 — intervention group
Group type: COMPARATOR
Intervention: Control group immobilized with plaster in plantar flexion for two weeks before starting functional exercise
Number of subjects: 64
Study 29355100 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease salience
Number of subjects: 0
Study 26510727 — intervention group
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV and MVA-RSV vaccines (various combinations)
Number of subjects: 70
Study 26510727 — intervention group
Group type: COMPARATOR
Intervention: Single dose of IM MVA-RSV
Number of subjects: 70
Study 26510727 — intervention group
Group type: EXPERIMENTAL
Intervention: IN or IM PanAd3-RSV prime and PanAd3-RSV or MVA-RSV boost vaccination
Number of subjects: 70
Study 26510727 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory measures of RSV-specific humoral and cellular immune responses
Number of subjects: 70
Study 23645476 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-variable model (including age, sex, estimated glomerular filtration rate (eGFR), albuminuria, calcium, phosphate, bicarbonate, albumin)
Number of subjects: 595
Study 23645476 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-variable model (including age, sex, eGFR, albuminuria)
Number of subjects: 595
Study 23645476 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-variable model (including age, sex, eGFR)
Number of subjects: 595
Study 23645476 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-variable model
Number of subjects: 595
Study 22204725 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus bevacizumab (7.5 mg/kg), given every 3 weeks for 5 or 6 cycles and continued for 12 additional cycles or until progression of disease.
Number of subjects: 1528
Study 22204725 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (carboplatin and paclitaxel), given every 3 weeks for 6 cycles.
Number of subjects: 1528
Study 22204725 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus bevacizumab (7.5 mg/kg).
Number of subjects: 1528
Study 22204725 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (carboplatin and paclitaxel).
Number of subjects: 1528
Study 18603290 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) technique
Number of subjects: 0
Study 18603290 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical and thermal cycling of fiber reinforced composite specimens
Number of subjects: 0
Study 17202550 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated group therapy
Number of subjects: 62
Study 17202550 — intervention group
Group type: COMPARATOR
Intervention: Group drug counseling
Number of subjects: 62
Study 15771038 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin + ursodeoxycholic acid
Number of subjects: 90
Study 15771038 — intervention group
Group type: COMPARATOR
Intervention: ursodeoxycholic acid alone
Number of subjects: 90
Study 12068338 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 0
Study 12068338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9627865 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cervical range of motion (ROM) measurements
Number of subjects: 40
Study 9627865 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive cervical range of motion (ROM) measurements
Number of subjects: 40
Study 8122496 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 0
Study 8122496 — intervention group
Group type: COMPARATOR
Intervention: 5 alpha‐pregnane‐3,20‐dione
Number of subjects: 0
Study 8122496 — intervention group
Group type: COMPARATOR
Intervention: 3 alpha‐hydroxy‐5 alpha‐pregnan‐20‐one
Number of subjects: 0
Study 2545765 — intervention group
Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT) 100U MRC, im
Number of subjects: 6
Study 2545765 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 2545765 — intervention group
Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT)
Number of subjects: 6
Study 335791 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (L-TP) 6 g daily with unilateral ECT
Number of subjects: 2
Study 335791 — intervention group
Group type: COMPARATOR
Intervention: Placebo with unilateral ECT
Number of subjects: 2
Study 335791 — intervention group
Group type: EXPERIMENTAL
Intervention: L-TP treatment
Number of subjects: 2
Study 335791 — intervention group
Group type: EXPERIMENTAL
Intervention: L-TP treatment with ECT
Number of subjects: 2
Study 29324569 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal sacrocervicopexy + subtotal hysterectomy
Number of subjects: 50
Study 29324569 — intervention group
Group type: COMPARATOR
Intervention: Vaginal sacrospinous fixation + vaginal hysterectomy
Number of subjects: 50
Study 29231339 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding combined with ginger-partitioned moxibustion (CECGP)
Number of subjects: 60
Study 29231339 — intervention group
Group type: COMPARATOR
Intervention: Regular acupuncture
Number of subjects: 60
Study 26551272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target of less than 120 mm Hg)
Number of subjects: 9361
Study 26551272 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target of less than 140 mm Hg)
Number of subjects: 9361
Study 26551272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 9361
Study 26551272 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 9361
Study 23519495 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 0
Study 23519495 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic cholecystectomy (TLC)
Number of subjects: 0
Study 21555684 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole plus goserelin (3.6 mg subcutaneously every 28 days)
Number of subjects: 0
Study 21555684 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 18635155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma group (lavender essential oil exposure)
Number of subjects: 30
Study 18635155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lavender exposure)
Number of subjects: 30
Study 16822129 — intervention group
Group type: EXPERIMENTAL
Intervention: Grasping and using an object (e.g., drinking from a cup)
Number of subjects: 0
Study 16822129 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger lifting in association with the object's position
Number of subjects: 0
Study 16822129 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic categorizations
Number of subjects: 0
Study 16822129 — intervention group
Group type: COMPARATOR
Intervention: Letter identification task
Number of subjects: 0
Study 14728085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone
Number of subjects: 0
Study 10901185 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 null genotype in patients with nephropathy
Number of subjects: 174
Study 10901185 — intervention group
Group type: COMPARATOR
Intervention: GSTM1 null genotype in patients without nephropathy
Number of subjects: 174
Study 10901185 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of GSTM1 null genotype frequency
Number of subjects: 174
Study 8791035 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg 5-HTP
Number of subjects: 14
Study 8791035 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg 5-HTP
Number of subjects: 14
Study 8791035 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg 5-HTP
Number of subjects: 14
Study 8791035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1591831 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of exercise training
Number of subjects: 17
Study 6233718 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational manipulation
Number of subjects: 81
Study 6233718 — intervention group
Group type: COMPARATOR
Intervention: Minimal massage and low-level electrostimulation (Control)
Number of subjects: 81
Study 30121131 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 138
Study 30121131 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 138
Study 27725941 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week physiotherapist-supervised and home-based exercise program
Number of subjects: 12
Study 27725941 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 12
Study 25607709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinecatechins 15% ointment BID
Number of subjects: 42
Study 25607709 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 42
Study 23121257 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg/day
Number of subjects: 50
Study 23121257 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day
Number of subjects: 50
Study 20887691 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral prevention intervention based on a cognitive model
Number of subjects: 1241
Study 20887691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1241
Study 20887691 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported likelihood to have sex
Number of subjects: 1241
Study 20887691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cubic term of the usp assessing three bifurcating variables (planning to have sex, intrinsic rewards from sex, self-efficacy for abstinence)
Number of subjects: 1241
Study 18558026 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally influenced educational intervention on healthy eating, physical activity, social support, and goal setting delivered in a group-discussion format for the first 6 months.
Number of subjects: 200
Study 15717109 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with myasthenia gravis (MG)
Number of subjects: 23
Study 15717109 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated autoantibody concentrations
Number of subjects: 23
Study 15717109 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 12598482 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded inspiratory resistance
Number of subjects: 10
Study 12598482 — intervention group
Group type: COMPARATOR
Intervention: No inspiratory resistance (control)
Number of subjects: 10
Study 11147733 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable extended-wear
Number of subjects: 50
Study 11147733 — intervention group
Group type: COMPARATOR
Intervention: Daily-disposable
Number of subjects: 50
Study 9301443 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF, 300 micrograms/day administered subcutaneously on days 3-6, 10-13, 17-20, and 24-27 during chemotherapy
Number of subjects: 41
Study 9301443 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered during chemotherapy
Number of subjects: 41
Study 8421111 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine, 100 ppm fluoride mouthrinse, rinsed 2x per day for 1 min with 15 ml for 6 weeks
Number of subjects: 102
Study 8421111 — intervention group
Group type: COMPARATOR
Intervention: Control rinse (minus active)
Number of subjects: 102
Study 3950051 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil 0.25 mg
Number of subjects: 0
Study 3950051 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil 0.75 mg
Number of subjects: 0
Study 3950051 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil 1.5 mg
Number of subjects: 0
Study 3950051 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil 3.0 mg
Number of subjects: 0
Study 3950051 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil (0.75 mg to 3.0 mg)
Number of subjects: 0
Study 3950051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26031804 — intervention group
Group type: EXPERIMENTAL
Intervention: Three home visits by a diabetes nurse
Number of subjects: 201
Study 26031804 — intervention group
Group type: COMPARATOR
Intervention: One telephone consultation (control group)
Number of subjects: 201
Study 24397879 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cystatin C measured at the end of operation (T4)
Number of subjects: 70
Study 24397879 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cystatin C measured 24 hours postoperatively (T5)
Number of subjects: 70
Study 24397879 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative serum cystatin C (T1)
Number of subjects: 70
Study 24397879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative serum cystatin C (T2/T3)
Number of subjects: 70
Study 22422589 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) using drug-eluting stents (DES) (n=556)
Number of subjects: 865
Study 22422589 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG) (n=309)
Number of subjects: 865
Study 22422589 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) using DES (n=556)
Number of subjects: 865
Study 22422589 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex stenting (n=196)
Number of subjects: 865
Study 22422589 — intervention group
Group type: COMPARATOR
Intervention: Simple stenting (n=360)
Number of subjects: 865
Study 20581352 — intervention group
Group type: COMPARATOR
Intervention: NaF mouthrinse (500 ppm F⁻)
Number of subjects: 24
Study 20581352 — intervention group
Group type: COMPARATOR
Intervention: AmF/NaF/SnCl₂ mouthrinse (500 ppm F⁻, 800 ppm Sn(2+))
Number of subjects: 24
Study 18672531 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP 400 mg per day
Number of subjects: 32
Study 18672531 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP 600 mg per day
Number of subjects: 32
Study 16306519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (1000 mg per day, increased to 3000 mg per day)
Number of subjects: 140
Study 12475577 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term low-dose heparin plus bedrest
Number of subjects: 10
Study 12475577 — intervention group
Group type: COMPARATOR
Intervention: Pregnant controls
Number of subjects: 10
Study 10390746 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha interferon
Number of subjects: 26
Study 10390746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8777623 — intervention group
Group type: EXPERIMENTAL
Intervention: MINS vasectomy
Number of subjects: 89
Study 8777623 — intervention group
Group type: COMPARATOR
Intervention: Standard vasectomy
Number of subjects: 89
Study 1503287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole intravenously every four hours, three times, starting from induction of anaesthesia (1.5 g for <60 kg, 2.5 g for 60-80 kg, 3 g for >80 kg)
Number of subjects: 114
Study 1503287 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at the same times
Number of subjects: 114
Study 6434168 — intervention group
Group type: COMPARATOR
Intervention: 2% sodium cromoglycate ophthalmic solution
Number of subjects: 40
Study 6434168 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% sodium cromoglycate ophthalmic solution
Number of subjects: 40
Study 31383366 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Glargine U100
Number of subjects: 34
Study 31383366 — intervention group
Group type: COMPARATOR
Intervention: NPH Insulin
Number of subjects: 34
Study 30128938 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 42
Study 30128938 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 42
Study 27792720 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin plus inulin (20 mg simvastatin, 7 g inulin)
Number of subjects: 60
Study 27792720 — intervention group
Group type: COMPARATOR
Intervention: simvastatin plus ezetimibe (20 mg simvastatin, 10 mg ezetimibe)
Number of subjects: 60
Study 24984088 — intervention group
Group type: EXPERIMENTAL
Intervention: Uni-nostril breathing (UNB)
Number of subjects: 12
Study 24984088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-nostril paced breathing (PB)
Number of subjects: 12
Study 24984088 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 12
Study 23046608 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (24 weeks)
Number of subjects: 90
Study 23046608 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) (10-12 weeks)
Number of subjects: 90
Study 20059361 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 grams/day
Number of subjects: 35
Study 20059361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 17586424 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (2.4 g daily for 8 weeks)
Number of subjects: 46
Study 17586424 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil, 2.4 g daily for 8 weeks)
Number of subjects: 46
Study 16304214 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 45
Study 16304214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 45
Study 16304214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 45
Study 12208577 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative external radiotherapy
Number of subjects: 0